AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$TGEN

Tecogen Q3 2026 Earnings Preview (TGEN:NYSE)

Tecogen (TGEN) will report Q3 2026 earnings on Nov 12. Analysts expect EPS of -$0.08 and revenue of $6.41M, down 10.7% year-over-year. The company has beaten EPS estimates in the past year, according to consensus estimates.

Original reporting
seekingalpha.com
Published Nov 11, 2026, 3:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 3:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tecogen Q3 2026 Earnings Preview (TGEN:NYSE) — source image
Source · seekingalpha.com
Decision brief

The 30-second read

$TGENNeutralMed
01

Why it matters

The preview sets expectations and may drive pre‑market positioning; actual results will determine price direction.

02

Market read

Earnings preview for a micro‑cap could cause notable price movement relative to its low float.

03

What to watch

Recent contract wins or regulatory developments not mentioned may shift the earnings outlook.

Relevance 5/10Novelty 4/10Timing: pre‑market today

Background

Tecogen is a small‑cap provider of distributed power generation solutions; its Q3 2026 earnings are anticipated by investors.

Company-level read

Ticker impact

$TGENNeutralHigh confidence
Context

Tecogen (TGEN) will announce Q3 2026 earnings on Nov 12 before the market opens, with consensus EPS of -$0.08 and revenue of $6.41M.

Expected impact

possible short‑term volatility around the earnings release

Evidence & confidence

The article provides only the schedule and consensus estimates, which traders may use to position for the upcoming surprise.

Market effects

Sector

Tecogen operates in the clean‑energy and power generation sector; earnings could influence peer valuations.

Regional

Impact limited to U.S. small‑cap energy stocks.

Global

Minimal global effect unless earnings surprise is large.

Counterpoint

What could challenge this read

If consensus expectations are overly pessimistic, the stock could rally on a modest beat.

Key entities

  • Company
    Tecogen Inc.

    U.S.-listed clean‑energy equipment manufacturer (ticker TGEN).

Read at source← All news

Related articles

$TGENMed

TECOGEN INC. (TGEN): Third Quarter 2026 Financial Results

TECOGEN INC. (TGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tecogen Reports Third Quarter 2026 Financial Results NORTH BILLERICA, Mass., November 11, 2026 - Tecogen Inc. (NYSE American:TGEN), a leading manufacturer of clean energy products, reported revenues of $7.87 million and net loss of $1.59 million for the three months ended Septemb

SEC EDGAR 8-K
$TGENMed

TECOGEN INC. (TGEN): Second Quarter 2026 Financial Results

TECOGEN INC. (TGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tecogen Reports Second Quarter 2026 Financial Results NORTH BILLERICA, Mass., August 12, 2026 - Tecogen Inc. (NYSE American:TGEN), a leading manufacturer of clean energy products, reported revenues of $5.75 million and net loss of $2.15 million for the three months ended June 30,

SEC EDGAR 8-K
$NEONMed

Neonode Reports Quarter Ended September 30, 2026 Financial Results

Neonode Inc. (NEON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release For Release, 9:10AM ET November 12, 2026 Neonode Reports Quarter Ended September 30, 2026 Financial Results STOCKHOLM, SWEDEN, November 12, 2026 — Neonode Inc. (NASDAQ: NEON) (“Neonode” or the “Company”) today reported financial results for the three an

SEC EDGAR 8-K
$UGMed

United-Guardian 3Q 2026: Revenue $3.49M, EPS $0.2 — 10-Q Summary

United-Guardian reported 3Q 2026 revenue of $3.49M, up 54% YoY, with EPS of $0.2. Growth was driven by pharmaceuticals, cosmetic ingredients, and medical lubricants. Pharmaceutical sales rose 29% due to Renacidin formulary coverage, while cosmetic ingredient sales climbed 187% after ASI resumed purchases. Medical lubricant sales increased 20%, and cost of sales fell to 46% of revenue.

tradingview.com